Uncategorized

LaFayette, N.Y. — Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, provided advanced technical assistance and scientific expertise for a research project on protein nanopore development and early disease detection. Ichor’s chief science officer, Dr. Aaron Wolfe, PhD, designed the research and participated in a peer-reviewed article on the project, “Disentangling the recognition complexity of a protein hub using a nanopore,” which appeared in a recent edition of Nature Communications. The paper covers the development and validation of a protein nanopore for the detection and quantification of WD40 report protein (WDR5), a chromatin-associated hub involved in epigenetic regulation of histone methylation. The nanopore sensor utilized was equipped with a 14-residue win motif of mixed lineage leukemia 4 methyltransferase (MLL4Win), a WDR5 ligand. The article describes the approach, which revealed a broad dynamic range of MLL4win-WDR5 interactions and three distant subpopulations of biding events,…

Ichor recently published a research article in Rejuvenation Research, a publisher of cutting-edge, peer-reviewed research on rejuvenation therapies in the laboratory and the clinic. In “Fluorescence-based detection of ferrous iron in senescent cells,” Ichor shares research showing the potential role of a newly discovered Fe2+ reactive probe for selective labeling of senescent cells in-vitro. Existing research in cellular senescence has been limited due to the lack of reliable biomarkers, the majority of which terminate the source materials when identified. Due to iron’s accumulation in various tissues with age, and recent studies demonstrating that its level increases in senescent cells, Ichor conducted a research study to determine the feasibility of using a new Fe2+ reactive probe, SiRhoNox-1, for selective labeling of senescent cells in-vitro without killing the existing cells. The findings of the research study show that SiRhoNox-1 selectivity labels live senescent cells faster and more specifically than current staining, such…

During Milwaukee Tech Week, a celebration for the regions emerging innovation and startup scene, Ichor Life Sciences CEO Kelsey Moody sat on a panel of judges for the Healthcare Innovation Pitch competition, where new companies had the opportunity to win cash prizes funded by the NIH and other regional sponsors. First place winners took home $10,000 for their company and received a years membership to the Matter startup incubator. Read more at the link below. https://www.bizjournals.com/milwaukee/inno/stories/news/2021/10/27/healthcare-innovation-pitch-competition-2021.html

Ichor Life Sciences (formerly Ichor Therapeutics), a premium pre-clinical contract research organization offering services in discovery through pharmacology, announces the publication of a peer-reviewed paper, “Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions,” in a recent issue of Biochemical Journal. The paper was co-authored by researchers at Ichor Life Sciences and faculty from the Department of Physics at Syracuse University. The WD40 repeat protein 5 (WDR5) gene is a major drug target for cancer treatment as inhibition of WDR5 can kill cancer cells. At the same time, WDR5 plays a role in healthy cell function and participates in the formation of numerous protein complexes. The Ichor Therapeutics-Syracuse University team studied how WDR5 interacts with a specific protein called SET1. “This work will accelerate drug development because researchers will know how WDR5 interacts with different binding partners and can therefore intelligently design drugs to…

Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces the hiring of three PhDs to further strengthen its research and pharmacology offerings, effective immediately. Jaeide Jawahill, PhD is joining Ichor Life Sciences as a Postdoctoral Researcher, Discovery. In his position, Dr. Jawahill will focus on protein purification, biophysics, automation and data processing. Prior to joining Ichor, he held adjunct teaching positions with Clarkson University in Chemical Reactor Analysis and Chemical Engineering, and completed his dissertation using complex domain computations to carry out difficult distillation column simulations. He also held research and testing positions with Kraft Foods and Four Elements Environmental Inc. Dr. Jawahill completed his PhD in Chemical Engineering from Clarkson University, and will report to the organization’s R&D laboratory in Potsdam, New York. Madeline Masi, PhD is also joining Ichor Life Sciences as a Postdoctoral Researcher, Discovery. In her role, Dr. Masi…

LaFayette, N.Y. — Ichor Life Sciences, a premium preclinical contract research organization offering services in discovery through pharmacology, announces it has formally completed the acquisition of Woodland Biosciences, Inc. The in vivo services for the study of metabolic diseases and oncology provided by the former Woodland Biosciences are now available through Ichor’s Pharmacology division. A preclinical contract research organization, Woodland Biosciences was previously located on the campus of Tufts Veterinary Medicine School. Woodland’s R&D facilities have fully relocated from Tufts University to Ichor’s facilities in LaFayette, New York. Dr. Michael Briggs, the President and CSO of Woodland Biosciences, continues as part of Ichor’s scientific leadership in pharmacology. Dr. Briggs has deep expertise and experience in pharmacology and has worked on several preclinical and clinical programs in hepatitis, liver fibrosis and oncology, among others. Ichor Life Sciences’ clients and partners will continue to benefit from Dr. Briggs’ involvement in study designs…

Ichor Life Sciences, a premium pre-clinical contract research organization offering services in discovery through pharmacology, announces that its attending veterinarian, Danique Wortel, Doctor of Veterinary Medicine (DVM), now also serves as the primary attending veterinarian at Trudeau Institute. Established in Saranac Lake, New York, in 1884, Trudeau Institute is a not-for-profit research institute with a world-renowned reputation for R&D in immunity to infectious disease. As an attending veterinarian, Dr. Wortel is responsible for the health, well-being, and clinical care of animals used in research, testing, teaching, and production. Dr. Wortel is a graduate of Cornell University-College of Veterinary Medicine and holder of a certificate in lab animal medicine. She has extensive technical experience in laboratory animal husbandry, xenograft models, genetic models, and microsurgery. A hands-on practitioner, Dr. Wortel has pioneered best-in-class practices such as positive reinforcement training with lab animals and oversaw the buildout of four vivariums at Ichor Life…

Ichor Therapeutics is now known as Ichor Life Sciences. The new name reflects Ichor Life Sciences’ emphasis on delivering premium pre-clinical contract research and custom programs in discovery through pharmacology from its R&D facilities in LaFayette and Potsdam, New York. Ichor Life Sciences services customers in numerous therapeutic areas, with specific expertise in oncology, metabolic disease, geriatrics, ophthalmology, and musculoskeletal disease. The company includes two divisions, Ichor Discovery, which provides protein manufacturing and scientific expertise in protein expression, structural biology, and biophysics, and Ichor Pharmacology, which provides services such as in vitro testing, histology, PK/PD, in vivo toxicology, and in vivo efficacy. According to Dr. Kelsey Moody, PhD, MBA, and chief executive officer, several distinguishing factors contribute to the ongoing evolution and growth of Ichor Life Sciences: World-class R&D laboratories, delivered entirely stateside—highlighted by an AAALAC-accredited vivarium, Ichor’s facilities include in vivo imaging, x-ray irradiation, complete surgical capabilities, metabolic caging…

We are pleased to share that effective September 30th, 2021, Woodland Biosciences, Inc. is now part of the Pharmacology Group at Ichor Life Sciences, Inc. Ichor is completing the integration of its contract research organization affiliates Icaria Life Sciences and Woodland Biosciences Ichor has completed a soft launch of its new website www.ichorlifesciences.com which features our services offerings in structure-based drug discovery and pharmacology Ichor and its affiliates will begin using @ichorlifesciences.com e-mail addresses. Existing Icaria and Woodland e-mails will forward to the appropraite user. These changes are operational in nature and should have little to no impact on daily interactions with outside parties. Staffing, facilities, and management remain unchanged.

Ichor Life Sciences, Inc. (formerly Ichor Therapeutics) has expanded to the North Country Incubator at Clarkson University as an anchor tenant to establish a biotechnology cluster in Potsdam, N.Y. Ichor studies fundamental mechanisms of aging to develop new classes of drugs dedicated to helping people live longer, healthier lives. CEO and Founder Dr. Kelsey Moody, a native of the North Country, said he recognizes the unique opportunities for industry and academic collaborations and the entrepreneurial spirit of Clarkson. “Ichor aims to build upon obvious synergies between its core competencies in structure-based drug discovery and translational medicine, and Clarkson’s deep expertise in chemistry, engineering, and health sciences,” Dr. Moody said. In collaboration with the Lewis School for Health Sciences, Ichor is expanding their protein science division and will occupy offices and wet laboratory space in Peyton Hall. As part of the expansion, Ichor will provide over $2 million in state-of-the-art equipment…